Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor

Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes

(2016) Rose Anderson et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

(2015) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

Saxagliptin: A Review in Type 2 Diabetes

(2015) Sohita Dhillon   DRUGS

Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

(2014) Julio Rosenstock et al.   DIABETES CARE

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes

(2014) Nayyar Iqbal et al.   Clinical Interventions in Aging

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

(2013) R. G. Moses et al.   DIABETES OBESITY & METABOLISM

Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes

(2013) J. Rosenstock et al.   DIABETIC MEDICINE

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

(2013) Chetan Karyekar et al.   Clinical Interventions in Aging

Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

(2012) David W. Boulton et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

(2012) Larry K. Golightly et al.   CLINICAL PHARMACOKINETICS

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women

(2012) V. V. Upreti et al.   DIABETES OBESITY & METABOLISM

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

(2012) C. F. Deacon et al.   DIABETES OBESITY & METABOLISM

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis

(2012) S.-C. Liu et al.   DIABETES OBESITY & METABOLISM

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial

(2012) Robert Frederich et al.   Diabetology & Metabolic Syndrome

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor

(2012) Aiying Wang et al.   BMC Pharmacology & Toxicology

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects

(2011) Vijay V. Upreti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

(2011) David W. Boulton et al.   CLINICAL PHARMACOKINETICS

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

(2011) Jean Doucet et al.   CURRENT MEDICAL RESEARCH AND OPINION

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

(2011) C. G. Patel et al.   DIABETES OBESITY & METABOLISM

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

(2011) R. R. Henry et al.   DIABETES OBESITY & METABOLISM

Dipeptidylpeptitase-4 Inhibitors (Gliptins)

(2010) André J. Scheen   CLINICAL PHARMACOKINETICS

Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects

(2010) Chirag G. Patel et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

(2009) J. Rosenstock et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

(2009) R. A. DeFronzo et al.   DIABETES CARE

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

(2009) M. Jadzinsky et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

(2009) A. Fura et al.   DRUG METABOLISM AND DISPOSITION

Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone

(2009) Priscilla Hollander et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

(2008) KS Fenner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS